Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Modulation of TARP γ8-Containing AMPA Receptors as a Novel Therapeutic Approach for Chronic Pain.

Knopp KL, Simmons RMA, Guo W, Adams BL, Gardinier KM, Gernert DL, Ornstein PL, Porter W, Reel J, Ding C, Wang H, Qian Y, Burris KD, Need A, Barth V, Swanson S, Catlow J, Witkin JM, Zwart R, Sher E, Choong KC, Wall TM, Schober D, Felder CC, Kato AS, Bredt DS, Nisenbaum ES.

J Pharmacol Exp Ther. 2019 Jun;369(3):345-363. doi: 10.1124/jpet.118.250126. Epub 2019 Mar 25.

PMID:
30910921
2.

Automated Electrophysiology Assays.

Priest BT, Cerne R, Krambis MJ, Schmalhofer WA, Wakulchik M, Wilenkin B, Burris KD.

In: Sittampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M, Auld D, Austin C, Baell J, Bejcek B, Caaveiro JMM, Chung TDY, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Haas JV, Inglese J, Iversen PW, Kahl SD, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Trask OJ Jr., Weidner JR, Wildey MJ, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2017 Mar 9.

3.

Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanism.

Kato AS, Burris KD, Gardinier KM, Gernert DL, Porter WJ, Reel J, Ding C, Tu Y, Schober DA, Lee MR, Heinz BA, Fitch TE, Gleason SD, Catlow JT, Yu H, Fitzjohn SM, Pasqui F, Wang H, Qian Y, Sher E, Zwart R, Wafford KA, Rasmussen K, Ornstein PL, Isaac JT, Nisenbaum ES, Bredt DS, Witkin JM.

Nat Med. 2016 Dec;22(12):1496-1501. doi: 10.1038/nm.4221. Epub 2016 Nov 7.

PMID:
27820603
4.

JBS Special Issue: Innovative Screening Methodologies to Identify New Compounds for the Treatment of Central Nervous System Disorders.

Burris KD, Dworetzky SI.

J Biomol Screen. 2016 Jun;21(5):425-6. doi: 10.1177/1087057116644231. No abstract available. Erratum in: J Biomol Screen. 2016 Aug;21(7):766.

PMID:
27206854
5.

Discovery of the First α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antagonist Dependent upon Transmembrane AMPA Receptor Regulatory Protein (TARP) γ-8.

Gardinier KM, Gernert DL, Porter WJ, Reel JK, Ornstein PL, Spinazze P, Stevens FC, Hahn P, Hollinshead SP, Mayhugh D, Schkeryantz J, Khilevich A, De Frutos O, Gleason SD, Kato AS, Luffer-Atlas D, Desai PV, Swanson S, Burris KD, Ding C, Heinz BA, Need AB, Barth VN, Stephenson GA, Diseroad BA, Woods TA, Yu H, Bredt D, Witkin JM.

J Med Chem. 2016 May 26;59(10):4753-68. doi: 10.1021/acs.jmedchem.6b00125. Epub 2016 Apr 29.

PMID:
27067148
6.

IonWorks Barracuda Assay for Assessment of State-Dependent Sodium Channel Modulators.

Cerne R, Wakulchik M, Krambis MJ, Burris KD, Priest BT.

Assay Drug Dev Technol. 2016 Mar;14(2):84-92. doi: 10.1089/adt.2015.677. Epub 2016 Feb 4.

PMID:
26844665
7.

An Integrated Approach for Screening and Identification of Positive Allosteric Modulators of N-Methyl-D-Aspartate Receptors.

Jambrina E, Cerne R, Smith E, Scampavia L, Cuadrado M, Findlay J, Krambis MJ, Wakulchik M, Chase P, Brunavs M, Burris KD, Gallagher P, Spicer TP, Ursu D.

J Biomol Screen. 2016 Jun;21(5):468-79. doi: 10.1177/1087057116628437. Epub 2016 Feb 2.

PMID:
26838761
8.

Optimization of a High-Throughput Assay for Calcium Channel Modulators on IonWorks Barracuda.

Cerne R, Wakulchik M, Li B, Burris KD, Priest BT.

Assay Drug Dev Technol. 2016 Mar;14(2):75-83. doi: 10.1089/adt.2015.678. Epub 2015 Dec 30.

PMID:
26716356
9.

Bias analyses of preclinical and clinical D2 dopamine ligands: studies with immediate and complex signaling pathways.

Brust TF, Hayes MP, Roman DL, Burris KD, Watts VJ.

J Pharmacol Exp Ther. 2015 Mar;352(3):480-93. doi: 10.1124/jpet.114.220293. Epub 2014 Dec 24.

10.

Drug-induced sensitization of adenylyl cyclase: assay streamlining and miniaturization for small molecule and siRNA screening applications.

Conley JM, Brust TF, Xu R, Burris KD, Watts VJ.

J Vis Exp. 2014 Jan 27;(83):e51218. doi: 10.3791/51218.

11.

Design, synthesis and evaluation of constrained tetrahydroimidazopyrimidine derivatives as antagonists of corticotropin-releasing factor type 1 receptor (CRF1R).

Vrudhula VM, Dasgupta B, Pin SS, Burris KD, Balanda LA, Fung LK, Fiedler T, Browman KE, Taber MT, Zhang J, Macor JE, Dubowchik GM.

Bioorg Med Chem Lett. 2010 Mar 15;20(6):1905-9. doi: 10.1016/j.bmcl.2010.01.127. Epub 2010 Feb 4.

PMID:
20185312
12.

Oxime carbamate--discovery of a series of novel FAAH inhibitors.

Sit SY, Conway CM, Xie K, Bertekap R, Bourin C, Burris KD.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. doi: 10.1016/j.bmcl.2009.11.080. Epub 2009 Nov 24.

PMID:
20036536
13.

Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.

Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, Molski TF, Yocca FD, Sharp T, Kikuchi T, Burris KD.

Psychopharmacology (Berl). 2007 Feb;190(3):373-82. Epub 2006 Nov 25.

PMID:
17242925
14.

Synthesis, structure-activity relationships, and anxiolytic activity of 7-aryl-6,7-dihydroimidazoimidazole corticotropin-releasing factor 1 receptor antagonists.

Han X, Michne JA, Pin SS, Burris KD, Balanda LA, Fung LK, Fiedler T, Browman KE, Taber MT, Zhang J, Dubowchik GM.

Bioorg Med Chem Lett. 2005 Sep 1;15(17):3870-3.

PMID:
15990298
15.

Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic.

Tadori Y, Miwa T, Tottori K, Burris KD, Stark A, Mori T, Kikuchi T.

Eur J Pharmacol. 2005 May 16;515(1-3):10-9.

PMID:
15894311
16.

Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile.

Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H, Burris KD, Altar CA, Nabeshima T.

J Psychopharmacol. 2004 Sep;18(3):375-83.

PMID:
15358981
17.

The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.

Aihara K, Shimada J, Miwa T, Tottori K, Burris KD, Yocca FD, Horie M, Kikuchi T.

Brain Res. 2004 Apr 2;1003(1-2):9-17.

PMID:
15019558
18.

Synthesis and SAR exploration of dinapsoline analogues.

Sit SY, Xie K, Jacutin-Porte S, Boy KM, Seanz J, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Verdoorn T, Johnson G, Nichols DE, Mailman RB.

Bioorg Med Chem. 2004 Feb 15;12(4):715-34.

PMID:
14759732
19.

2-arylaminothiazoles as high-affinity corticotropin-releasing factor 1 receptor (CRF1R) antagonists: synthesis, binding studies and behavioral efficacy.

Dubowchik GM, Michne JA, Zuev D, Schwartz W, Scola PM, James CA, Ruediger EH, Pin SS, Burris KD, Balanda LA, Gao Q, Wu D, Fung L, Fiedler T, Browman KE, Taber MT, Zhang J.

Bioorg Med Chem Lett. 2003 Nov 17;13(22):3997-4000.

PMID:
14592493
20.

Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone.

Nakai S, Hirose T, Uwahodo Y, Imaoka T, Okazaki H, Miwa T, Nakai M, Yamada S, Dunn B, Burris KD, Molinoff PB, Tottori K, Altar CA, Kikuchi T.

Eur J Pharmacol. 2003 Jul 4;472(1-2):89-97.

PMID:
12860477
21.

(+)-Dinapsoline: an efficient synthesis and pharmacological profile of a novel dopamine agonist.

Sit SY, Xie K, Jacutin-Porte S, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Wong H, Zhu J, Krishnananthan S, Gao Q, Verdoorn T, Johnson G.

J Med Chem. 2002 Aug 15;45(17):3660-8.

PMID:
12166939
22.

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.

Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB.

J Pharmacol Exp Ther. 2002 Jul;302(1):381-9.

PMID:
12065741
23.

Regulation of D2 and D3 receptors in transfected cells by agonists and antagonists.

Burris KD, Fausing SM, Molinoff PB.

Adv Pharmacol. 1998;42:443-6. No abstract available.

PMID:
9327934
24.

Expression of the human 5-hydroxytryptamine1A receptor in Sf9 cells. Reconstitution of a coupled phenotype by co-expression of mammalian G protein subunits.

Butkerait P, Zheng Y, Hallak H, Graham TE, Miller HA, Burris KD, Molinoff PB, Manning DR.

J Biol Chem. 1995 Aug 4;270(31):18691-9.

25.

Lack of discrimination by agonists for D2 and D3 dopamine receptors.

Burris KD, Pacheco MA, Filtz TM, Kung MP, Kung HF, Molinoff PB.

Neuropsychopharmacology. 1995 Jul;12(4):335-45.

26.

Characterization of binding sites for [125I]R(+)trans-7-OH-PIPAT in rat brain.

Kung MP, Chumpradit S, Frederick D, Garner S, Burris KD, Molinoff PB, Kung HF.

Naunyn Schmiedebergs Arch Pharmacol. 1994 Dec;350(6):611-7.

PMID:
7708118
27.

Characterization of [125I](R)-trans-7-hydroxy-2-[N-propyl-N-(3'-iodo-2'-propenyl)amino] tetralin binding to dopamine D3 receptors in rat olfactory tubercle.

Burris KD, Filtz TM, Chumpradit S, Kung MP, Foulon C, Hensler JG, Kung HF, Molinoff PB.

J Pharmacol Exp Ther. 1994 Feb;268(2):935-42.

PMID:
8114008
29.

(+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5HT1C receptor agonist.

Burris KD, Breeding M, Sanders-Bush E.

J Pharmacol Exp Ther. 1991 Sep;258(3):891-6.

PMID:
1679849
30.

Phosphoinositide hydrolysis linked 5-HT2 receptors in fibroblasts from choroid plexus.

Barker EL, Burris KD, Sanders-Bush E.

Brain Res. 1991 Jun 28;552(2):330-2.

PMID:
1655172
31.

Serotonin receptors and phosphatidylinositol turnover.

Sanders-Bush E, Tsutsumi M, Burris KD.

Ann N Y Acad Sci. 1990;600:224-35; discussion 235-6. Review. No abstract available.

PMID:
2252311
32.
33.

Peroxidation of brain lipids following cyanide intoxication in mice.

Johnson JD, Conroy WG, Burris KD, Isom GE.

Toxicology. 1987 Oct 12;46(1):21-8.

PMID:
3660418

Supplemental Content

Loading ...
Support Center